CommentCan radiomics personalise immunotherapy?
References (10)
- et al.
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Lancet Oncol
(2016) - et al.
Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer
JAMA Oncol
(2016) - et al.
First-line nivolumab in stage IV or recurrent non-small-cell lung cancer
N Engl J Med
(2017) - et al.
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients
Proc Natl Acad Sci USA
(2017) - et al.
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Nat Med
(2018)
Cited by (22)
Biomarkers for response to immunotherapy in hepatobiliary malignancies
2022, Hepatobiliary and Pancreatic Diseases InternationalCitation Excerpt :Further studies are needed to investigate the value of PD-L2 in predicting immunotherapy response for HCC patients. Radiomics-based biomarkers represent another promising non-invasive approach in personalizing cancer immunotherapy [57–59]. One of the earliest studies to investigate the value of radiomics in predicting immunotherapy response was reported by Sun and colleagues in 135 patients with advanced solid malignant tumors [60].
Radiomics and “radi-…omics” in cancer immunotherapy: a guide for clinicians
2020, Critical Reviews in Oncology/HematologyCitation Excerpt :Calibration can be defined as the agreement between model predictions and observed outcomes, and it is typically reported by using a calibration plot and calibration-in-the-large/slope (Lambin et al., 2012; Steyerberg et al., 2010). Radiomics could be a helpful tool in cancer immunotherapy for optimal patient selection (El Naqa I, Ten Haken RK, 2018). It may act as a non-invasive digital biopsy technique able to quantify tumor T-cell infiltration, to support personalized immunotherapy interventions, and to longitudinally monitor the therapeutic response above the traditional dimensional criteria (Solinas et al., 2017; Porcu et al., 2018).
The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer
2020, Archivos de BronconeumologiaCitation Excerpt :They will help identify responders non-invasively before starting immunotherapy (depending on PD-1/PD-L1 expression) or differentiate pseudoprogression from real progression (depending on T cell activation or non-activation).35 Radiomics (a new term used to describe the extraction of advanced quantitative characteristics from CT or magnetic resonance images) may correlate with underlying molecular and genetic characteristics (radiogenomics) and with different tumor phenotypes, assisting in the development of better biomarkers in the future.67–69 As we gradually overcome these challenges, the diagnostic management of patients will improve, probably impacting positively on their survival and quality of life; these new techniques and strategies may even let us hope that the curing of metastatic LC is not just a dream.
Application of molecular imaging technology in tumor immunotherapy
2020, Cellular ImmunologyCitation Excerpt :In the immune response phase, tumors are characterized by dense functional CD8 cell infiltration, increased expression of interferon-gamma, and cell checkpoint markers (e.g., PD-L1), which respond to immunotherapy at this stage. In the immune rejection phase, several biological signals are generated in the tumor, including transforming growth factor-β signal, activation of myeloid-derived suppressor cells, and angiogenic signals, suggesting inhibition of T-cell infiltration [22,23]. The immunodeficiency phase is characterized by low CD8 cell infiltration.
Association between radiomics features of DCE-MRI and CD8<sup>+</sup> and CD4<sup>+</sup> TILs in advanced gastric cancer
2023, Pathology and Oncology Research